These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

277 related articles for article (PubMed ID: 24416140)

  • 1. Pharmacokinetics, brain delivery, and efficacy in brain tumor-bearing mice of glutathione pegylated liposomal doxorubicin (2B3-101).
    Gaillard PJ; Appeldoorn CC; Dorland R; van Kregten J; Manca F; Vugts DJ; Windhorst B; van Dongen GA; de Vries HE; Maussang D; van Tellingen O
    PLoS One; 2014; 9(1):e82331. PubMed ID: 24416140
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Enhanced doxorubicin delivery to the brain administered through glutathione PEGylated liposomal doxorubicin (2B3-101) as compared with generic Caelyx,(®)/Doxil(®)--a cerebral open flow microperfusion pilot study.
    Birngruber T; Raml R; Gladdines W; Gatschelhofer C; Gander E; Ghosh A; Kroath T; Gaillard PJ; Pieber TR; Sinner F
    J Pharm Sci; 2014 Jul; 103(7):1945-1948. PubMed ID: 24801480
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics, efficacy and toxicity of different pegylated liposomal doxorubicin formulations in preclinical models: is a conventional bioequivalence approach sufficient to ensure therapeutic equivalence of pegylated liposomal doxorubicin products?
    Mamidi RN; Weng S; Stellar S; Wang C; Yu N; Huang T; Tonelli AP; Kelley MF; Angiuoli A; Fung MC
    Cancer Chemother Pharmacol; 2010 Nov; 66(6):1173-84. PubMed ID: 20661737
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Convection-enhanced delivery of a topoisomerase I inhibitor (nanoliposomal topotecan) and a topoisomerase II inhibitor (pegylated liposomal doxorubicin) in intracranial brain tumor xenografts.
    Yamashita Y; Krauze MT; Kawaguchi T; Noble CO; Drummond DC; Park JW; Bankiewicz KS
    Neuro Oncol; 2007 Jan; 9(1):20-8. PubMed ID: 17018695
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Short-time focused ultrasound hyperthermia enhances liposomal doxorubicin delivery and antitumor efficacy for brain metastasis of breast cancer.
    Wu SK; Chiang CF; Hsu YH; Lin TH; Liou HC; Fu WM; Lin WL
    Int J Nanomedicine; 2014; 9():4485-94. PubMed ID: 25278753
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The comparison of biodistribution of glutathione PEGylated nanoliposomal doxorubicin formulations prepared by pre-insertion and post-insertion methods for brain delivery in normal mice.
    Mehrabian A; Dadpour S; Mashreghi M; Zarqi J; Askarizadeh A; Badiee A; Arabi L; Moosavian SA; Jaafari MR
    IET Nanobiotechnol; 2023 Apr; 17(2):112-124. PubMed ID: 36594666
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preclinical studies of pegylated- and non-pegylated liposomal forms of doxorubicin as radiosensitizer on orthotopic high-grade glioma xenografts.
    Chastagner P; Sudour H; Mriouah J; Barberi-Heyob M; Bernier-Chastagner V; Pinel S
    Pharm Res; 2015 Jan; 32(1):158-66. PubMed ID: 25048636
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preclinical evaluation of convection-enhanced delivery of liposomal doxorubicin to treat pediatric diffuse intrinsic pontine glioma and thalamic high-grade glioma.
    Sewing ACP; Lagerweij T; van Vuurden DG; Meel MH; Veringa SJE; Carcaboso AM; Gaillard PJ; Peter Vandertop W; Wesseling P; Noske D; Kaspers GJL; Hulleman E
    J Neurosurg Pediatr; 2017 May; 19(5):518-530. PubMed ID: 28291423
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Liposomal formulation of Galbanic acid improved therapeutic efficacy of pegylated liposomal Doxorubicin in mouse colon carcinoma.
    Nik ME; Malaekeh-Nikouei B; Amin M; Hatamipour M; Teymouri M; Sadeghnia HR; Iranshahi M; Jaafari MR
    Sci Rep; 2019 Jul; 9(1):9527. PubMed ID: 31267009
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeted glioma chemotherapy by cyclic RGD peptide-functionalized reversibly core-crosslinked multifunctional poly(ethylene glycol)-b-poly(ε-caprolactone) micelles.
    Fang Y; Jiang Y; Zou Y; Meng F; Zhang J; Deng C; Sun H; Zhong Z
    Acta Biomater; 2017 Mar; 50():396-406. PubMed ID: 28065871
    [TBL] [Abstract][Full Text] [Related]  

  • 11. EGFR Targeting of Liposomal Doxorubicin Improves Recognition and Suppression of Non-Small Cell Lung Cancer.
    Moles E; Chang DW; Mansfeld FM; Duly A; Kimpton K; Logan A; Howard CB; Thurecht KJ; Kavallaris M
    Int J Nanomedicine; 2024; 19():3623-3639. PubMed ID: 38660023
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics and efficacy of PEGylated liposomal doxorubicin in an intracranial model of breast cancer.
    Anders CK; Adamo B; Karginova O; Deal AM; Rawal S; Darr D; Schorzman A; Santos C; Bash R; Kafri T; Carey L; Miller CR; Perou CM; Sharpless N; Zamboni WC
    PLoS One; 2013; 8(5):e61359. PubMed ID: 23650496
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Asiatic acid enhances intratumor delivery and the antitumor effect of pegylated liposomal doxorubicin by reducing tumor-stroma collagen.
    Fang L; Kong SS; Zhong LK; Wang CM; Liu YJ; Ding HY; Sun J; Zhang YW; Li FZ; Huang P
    Acta Pharmacol Sin; 2019 Apr; 40(4):539-545. PubMed ID: 29921887
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Co-delivery of doxorubicin and erlotinib through liposomal nanoparticles for glioblastoma tumor regression using an in vitro brain tumor model.
    Lakkadwala S; Singh J
    Colloids Surf B Biointerfaces; 2019 Jan; 173():27-35. PubMed ID: 30261346
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A comparison of changes to doxorubicin pharmacokinetics, antitumor activity, and toxicity mediated by PEGylated dendrimer and PEGylated liposome drug delivery systems.
    Kaminskas LM; McLeod VM; Kelly BD; Sberna G; Boyd BJ; Williamson M; Owen DJ; Porter CJ
    Nanomedicine; 2012 Jan; 8(1):103-11. PubMed ID: 21704192
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Direct comparison of two pegylated liposomal doxorubicin formulations: is AUC predictive for toxicity and efficacy?
    Cui J; Li C; Guo W; Li Y; Wang C; Zhang L; Zhang L; Hao Y; Wang Y
    J Control Release; 2007 Apr; 118(2):204-15. PubMed ID: 17239468
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Therapeutic efficacy of aldoxorubicin in an intracranial xenograft mouse model of human glioblastoma.
    Marrero L; Wyczechowska D; Musto AE; Wilk A; Vashistha H; Zapata A; Walker C; Velasco-Gonzalez C; Parsons C; Wieland S; Levitt D; Reiss K; Prakash O
    Neoplasia; 2014 Oct; 16(10):874-82. PubMed ID: 25379024
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dose dependency of pharmacokinetics and therapeutic efficacy of pegylated liposomal doxorubicin (DOXIL) in murine models.
    Gabizon A; Tzemach D; Mak L; Bronstein M; Horowitz AT
    J Drug Target; 2002 Nov; 10(7):539-48. PubMed ID: 12683721
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Improvement in the drug delivery and anti-tumor efficacy of PEGylated liposomal doxorubicin by targeting RNA aptamers in mice bearing breast tumor model.
    Moosavian SA; Abnous K; Badiee A; Jaafari MR
    Colloids Surf B Biointerfaces; 2016 Mar; 139():228-36. PubMed ID: 26722819
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dual functionalized liposomes for efficient co-delivery of anti-cancer chemotherapeutics for the treatment of glioblastoma.
    Lakkadwala S; Dos Santos Rodrigues B; Sun C; Singh J
    J Control Release; 2019 Aug; 307():247-260. PubMed ID: 31252036
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.